Phase I Clinical Trials with Anticancer Agents

  • Stephen Leong
  • Justin Call
  • Alex A. Adjei
  • Wells Messersmith
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Although the term “phase I” is used to describe numerous trial designs, the overarching goal of a phase I study is to determine the optimal dose and/or schedule of a therapy for evaluation in the phase II setting. Phase I trials typically test different doses of an anticancer agent(s) in various neoplastic diseases, with safety evaluation as a main objective. These studies range from first-in-human trials of novel single agents to new combinations of FDA-approved therapies. Frequently, pharmacokinetic studies are incorporated in phase I clinical trials, in order to determine drug exposure and clearance. In addition, phase I studies may include biomarkers of drug effects such as functional imaging or direct measurement of drug effects on either tumor biopsies and/or normal tissue samples.


Placebo Toxicity Europe Lymphoma Leukemia 


  1. 1.
    Roberts TG, Jr., Goulart BH, Squitieri L, et al: Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130–40, 2004PubMedCrossRefGoogle Scholar
  2. 2.
    Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138–47, 1997PubMedCrossRefGoogle Scholar
  3. 3.
    O’Quigley J, Pepe M, Fisher L: Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46:33–48, 1990PubMedCrossRefGoogle Scholar
  4. 4.
    Chevert S: The continual reassessment method in cancer phase I clinical trials: a simulation study. Stat Med 12:1093–108, 1993CrossRefGoogle Scholar
  5. 5.
    Goodman SN, Zahurak ML, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149–61, 1995PubMedCrossRefGoogle Scholar
  6. 6.
    Koyfman SA, Agrawal M, Garrett-Mayer E, et al: Risks and benefits associated with novel phase 1 oncology trial designs. Cancer 110:1115–24, 2007PubMedCrossRefGoogle Scholar
  7. 7.
    Skolnik JM, Barrett JS, Jayaraman B, et al: Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol 26:190–5, 2008PubMedCrossRefGoogle Scholar
  8. 8.
    Mahmoud HH, Hurwitz CA, Roberts WM, et al: Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet 342:1394–5, 1993PubMedCrossRefGoogle Scholar
  9. 9.
    Eisenhauer EA, O’Dwyer PJ, Christian M, et al: Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684–92, 2000PubMedGoogle Scholar
  10. 10.
    Von Hoff DD, Turner J: Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115–22, 1991Google Scholar
  11. 11.
    Mahmood I: A Bayesian approach for the estimation of pharmacokinetic parameters in children. Am J Ther 10:88–92, 2003PubMedCrossRefGoogle Scholar
  12. 12.
    Contrera JF, Matthews EJ, Kruhlak NL, et al: Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Regul Toxicol Pharmacol 40:185–206, 2004PubMedCrossRefGoogle Scholar
  13. 13.
  14. 14.
    Shankar LK, Hoffman JM, Bacharach S, et al: Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47:1059–66, 2006PubMedGoogle Scholar
  15. 15.
    Parulekar WR, Eisenhauer EA: Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 96:990–7, 2004PubMedCrossRefGoogle Scholar
  16. 16.
    Agrawal M, Emanuel EJ: Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA 290:1075–82, 2003PubMedCrossRefGoogle Scholar
  17. 17.
    Freireich EJ: Ethical considerations in cancer chemotherapy. Annu Rev Pharmacol Toxicol 19:547–57, 1979PubMedCrossRefGoogle Scholar
  18. 18.
    Joffe S, Miller FG: Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol 24:2987–90, 2006PubMedCrossRefGoogle Scholar
  19. 19.
    Lipsett MB: On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA 248:941–2, 1982PubMedCrossRefGoogle Scholar
  20. 20.
    Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895–904, 2005PubMedCrossRefGoogle Scholar
  21. 21.
    Daugherty CK, Banik DM, Janish L, et al: Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB 22:6–14, 2000PubMedCrossRefGoogle Scholar
  22. 22.
    Joffe S, Cook EF, Cleary PD, et al: Quality of informed consent: a new measure of understanding among research subjects. J Natl Cancer Inst 93:139–47, 2001PubMedCrossRefGoogle Scholar
  23. 23.
    Horng S, Emanuel EJ, Wilfond B, et al: Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 347:2134–40, 2002PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Stephen Leong
  • Justin Call
  • Alex A. Adjei
    • 1
  • Wells Messersmith
  1. 1.Department of MedicineRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations